Abstract
Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 96-98 |
| Number of pages | 3 |
| Journal | World Journal of Clinical Oncology |
| Volume | 6 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Oct 10 2015 |
Fingerprint
Keywords
- Programmed cell death-1
- Targeted therapy
- Thymic carcinoma
- Thymic epithelial tumors
- Thymoma
ASJC Scopus subject areas
- Oncology
Cite this
New findings on thymic epithelial tumors : Something is changing. / Berardi, Rossana; Morgese, Francesca; Garassino, Marina Chiara; Cascinu, Stefano.
In: World Journal of Clinical Oncology, Vol. 6, No. 5, 10.10.2015, p. 96-98.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New findings on thymic epithelial tumors
T2 - Something is changing
AU - Berardi, Rossana
AU - Morgese, Francesca
AU - Garassino, Marina Chiara
AU - Cascinu, Stefano
PY - 2015/10/10
Y1 - 2015/10/10
N2 - Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.
AB - Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.
KW - Programmed cell death-1
KW - Targeted therapy
KW - Thymic carcinoma
KW - Thymic epithelial tumors
KW - Thymoma
UR - http://www.scopus.com/inward/record.url?scp=84945129886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945129886&partnerID=8YFLogxK
U2 - 10.5306/wjco.v6.i5.96
DO - 10.5306/wjco.v6.i5.96
M3 - Article
AN - SCOPUS:84945129886
VL - 6
SP - 96
EP - 98
JO - World Journal of Clinical Oncology
JF - World Journal of Clinical Oncology
SN - 2218-4333
IS - 5
ER -